Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2021 - 2023)

Palvella Therapeutics (PVLA) has reported Depreciation & Amortization (CF) for 10 consecutive years, with -$198000.0 the latest figure, recorded in Q4 2023.

• In Q4 2023, Depreciation & Amortization (CF) fell 134.43% year-over-year to -$198000.0; the TTM figure through Sep 2024 stood at -$198000.0 (down 107.4% YoY), while the FY2023 annual figure was $1.9 million, down 31.26% from the prior year.
• Depreciation & Amortization (CF) declined to -$198000.0 in Q4 2023 per PVLA's latest filing, from $739000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $845000.0 in Q1 2022 and bottomed at -$198000.0 in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $503800.0 across 5 years, with a median of $606500.0 in 2021.
• Annual changes were most pronounced in 2020 — Depreciation & Amortization (CF) soared 1161.9% — and 2023, when it slumped 134.43%.
• Palvella Therapeutics' Depreciation & Amortization (CF) stood at $265000.0 in 2019, then surged by 159.62% to $688000.0 in 2020, then decreased by 11.48% to $609000.0 in 2021, then fell by 5.58% to $575000.0 in 2022, then plunged by 134.43% to -$198000.0 in 2023.
• Business Quant data shows PVLA's Depreciation & Amortization (CF) at -$198000.0 in Q4 2023, $739000.0 in Q3 2023, and $758000.0 in Q2 2023.